Lurbinectedin is a medication used in cancer treatment, specifically for certain types of tumors. While the sources provided do not directly address the impact of lurbinectedin on the immune system, they do provide valuable information about the drug's mechanism of action and its potential side effects.

According to the Drug Patent Watch website, lurbinectedin is a synthetic compound derived from a marine organism called Ecteinascidia turbinata. It works by targeting specific DNA structures and inhibiting the transcription process, which ultimately leads to cell death in cancer cells [1]. This mechanism of action primarily affects the tumor cells themselves and does not specifically target the immune system.

The article published in the National Center for Biotechnology Information (NCBI) provides a comprehensive overview of lurbinectedin's pharmacology, efficacy, and safety. It mentions that lurbinectedin has shown promising results in preclinical and clinical studies, particularly against small cell lung cancer and other solid tumors [2]. However, the article does not delve into the drug's impact on the immune system.

The clinical trial listed on the National Cancer Institute's website provides information about a specific trial involving lurbinectedin. The trial aims to evaluate the drug's efficacy and safety in combination with other medications for the treatment of advanced solid tumors [3]. While the trial may shed light on the overall impact of lurbinectedin on the immune system, the specific details are not available in the provided source.

To summarize, the sources provided do not directly address how lurbinectedin affects the immune system during treatment. However, they do provide valuable information about the drug's mechanism of action and its potential efficacy and safety in cancer treatment.

Sources:
[1] Drug Patent Watch. Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] National Center for Biotechnology Information. Lurbinectedin: A Review of Its Pharmacology, Efficacy, and Safety in the Treatment of Solid Tumors. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791417/
[3] National Cancer Institute. A Study of Lurbinectedin (PM01183) in Combination With Other Anticancer Agents in Patients With Advanced Solid Tumors. Retrieved from https://www.cancer.gov/clinicaltrials/NCI-2022-07798